Brief: Olix Pharmaceuticals Publishes Preclinical Research Demonstrating Olx104c’S Potential As An Effective Treatment For Hair Loss
22/11/2022 13:15
Nov 22 (Reuters) - OliX Pharmaceuticals Inc 226950.KQ :
* OLIX PHARMACEUTICALS PUBLISHES PRECLINICAL RESEARCH
DEMONSTRATING OLX104C’S POTENTIAL AS AN EFFECTIVE TREATMENT FOR
HAIR LOSS
* OLIX PHARMACEUTICALS INC - DEMONSTRATED EFFICACY OF AR
REDUCTION, HAIR LOSS INHIBITION, AND LONG DURATION OF ACTION
* OLIX PHARMACEUTICALS INC - PLAN TO SUBMIT A HREA FOR PHASE
1
CLINICAL TRIAL NEAR END OF 2022
Source text for Eikon: ID:nBw2P6Jsha
Further company coverage: 226950.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on OliX Pharmaceuticals
See all newsBrief: Olix Pharmaceuticals Receives Milestone Payment From L'oreal
Brief: OliX And Lilly Enter Global Licensing Agreement For Mash And Other Cardiometabolic Indications
Brief: Olix Pharmaceuticals Commences Patient Dosing In Phase 1 Clinical Trial Of Olx75016
Brief: Olix Pharmaceuticals Receives Hrec Approval To Initiate Phase 1 Clinical Trial Of Nash And Obesity Drug
Brief: OliX Pharmaceuticals Administers First Patient In Phase 1 Clinical Study of Androgenic Alopecia Treatment